JP2024518319A - 分析用ｈｐｌｃ - Google Patents

分析用ｈｐｌｃ Download PDF

Info

Publication number
JP2024518319A
JP2024518319A JP2023565467A JP2023565467A JP2024518319A JP 2024518319 A JP2024518319 A JP 2024518319A JP 2023565467 A JP2023565467 A JP 2023565467A JP 2023565467 A JP2023565467 A JP 2023565467A JP 2024518319 A JP2024518319 A JP 2024518319A
Authority
JP
Japan
Prior art keywords
mobile phase
organic solvent
acid
fluoride
radiopharmaceutical
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2023565467A
Other languages
English (en)
Japanese (ja)
Other versions
JP2024518319A5 (enExample
Inventor
クラーク，アラン
エンゲルブレヒト，ヘンドリック，ペトルス
グリッグ，ジュリアン
アハメド カーン，イムティアズ
ウィケネ，クリスチャン
マクロビー，グレイム
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
GE Healthcare Ltd
Original Assignee
GE Healthcare Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by GE Healthcare Ltd filed Critical GE Healthcare Ltd
Publication of JP2024518319A publication Critical patent/JP2024518319A/ja
Publication of JP2024518319A5 publication Critical patent/JP2024518319A5/ja
Pending legal-status Critical Current

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N30/00—Investigating or analysing materials by separation into components using adsorption, absorption or similar phenomena or using ion-exchange, e.g. chromatography or field flow fractionation
    • G01N30/02—Column chromatography
    • G01N30/88—Integrated analysis systems specially adapted therefor, not covered by a single one of the groups G01N30/04 - G01N30/86
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N30/00—Investigating or analysing materials by separation into components using adsorption, absorption or similar phenomena or using ion-exchange, e.g. chromatography or field flow fractionation
    • G01N30/02—Column chromatography
    • G01N30/26—Conditioning of the fluid carrier; Flow patterns
    • G01N30/28—Control of physical parameters of the fluid carrier
    • G01N30/34—Control of physical parameters of the fluid carrier of fluid composition, e.g. gradient
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/0093—Radioactive materials
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/15—Medicinal preparations ; Physical properties thereof, e.g. dissolubility
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N30/00—Investigating or analysing materials by separation into components using adsorption, absorption or similar phenomena or using ion-exchange, e.g. chromatography or field flow fractionation
    • G01N30/02—Column chromatography
    • G01N2030/022—Column chromatography characterised by the kind of separation mechanism
    • G01N2030/027—Liquid chromatography
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N30/00—Investigating or analysing materials by separation into components using adsorption, absorption or similar phenomena or using ion-exchange, e.g. chromatography or field flow fractionation
    • G01N30/02—Column chromatography
    • G01N30/88—Integrated analysis systems specially adapted therefor, not covered by a single one of the groups G01N30/04 - G01N30/86
    • G01N2030/8809—Integrated analysis systems specially adapted therefor, not covered by a single one of the groups G01N30/04 - G01N30/86 analysis specially adapted for the sample
    • G01N2030/884—Integrated analysis systems specially adapted therefor, not covered by a single one of the groups G01N30/04 - G01N30/86 analysis specially adapted for the sample organic compounds
    • G01N2030/8845—Integrated analysis systems specially adapted therefor, not covered by a single one of the groups G01N30/04 - G01N30/86 analysis specially adapted for the sample organic compounds involving halogenated organic compounds
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N30/00—Investigating or analysing materials by separation into components using adsorption, absorption or similar phenomena or using ion-exchange, e.g. chromatography or field flow fractionation
    • G01N30/02—Column chromatography
    • G01N30/88—Integrated analysis systems specially adapted therefor, not covered by a single one of the groups G01N30/04 - G01N30/86
    • G01N2030/8809—Integrated analysis systems specially adapted therefor, not covered by a single one of the groups G01N30/04 - G01N30/86 analysis specially adapted for the sample
    • G01N2030/8859—Integrated analysis systems specially adapted therefor, not covered by a single one of the groups G01N30/04 - G01N30/86 analysis specially adapted for the sample inorganic compounds

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • General Physics & Mathematics (AREA)
  • Immunology (AREA)
  • Pathology (AREA)
  • Engineering & Computer Science (AREA)
  • Food Science & Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Steroid Compounds (AREA)
  • Polysaccharides And Polysaccharide Derivatives (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Treatment Of Liquids With Adsorbents In General (AREA)
JP2023565467A 2021-04-26 2022-04-26 分析用ｈｐｌｃ Pending JP2024518319A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GB2105950.6 2021-04-26
GBGB2105950.6A GB202105950D0 (en) 2021-04-26 2021-04-26 Analytical HPLC
PCT/EP2022/061004 WO2022229155A1 (en) 2021-04-26 2022-04-26 Analytical hplc

Publications (2)

Publication Number Publication Date
JP2024518319A true JP2024518319A (ja) 2024-05-01
JP2024518319A5 JP2024518319A5 (enExample) 2025-05-09

Family

ID=76193425

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2023565467A Pending JP2024518319A (ja) 2021-04-26 2022-04-26 分析用ｈｐｌｃ

Country Status (12)

Country Link
US (1) US20240302338A1 (enExample)
EP (1) EP4330662B1 (enExample)
JP (1) JP2024518319A (enExample)
KR (1) KR20240000562A (enExample)
CN (1) CN117222890A (enExample)
AU (1) AU2022264815A1 (enExample)
CA (1) CA3217818A1 (enExample)
ES (1) ES3050308T3 (enExample)
GB (1) GB202105950D0 (enExample)
IL (1) IL307946A (enExample)
PL (1) PL4330662T3 (enExample)
WO (1) WO2022229155A1 (enExample)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB201915206D0 (en) 2019-10-21 2019-12-04 Ge Healthcare Ltd Use of cyclodextrins as a radiostabilizer
CN119688861A (zh) * 2024-11-29 2025-03-25 中国辐射防护研究院 一种生物样本中18f-psma-1007放化纯的液相色谱分析方法

Citations (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH07503960A (ja) * 1992-02-14 1995-04-27 マリンクロッド・インコーポレイテッド 安定化放射性医薬品キット
JP2006514915A (ja) * 2002-03-01 2006-05-18 ダイアックス、コープ Ｋｄｒおよびｖｅｇｆ／ｋｄｒ結合ペプチドならびに診断および治療におけるその使用
JP2007010487A (ja) * 2005-06-30 2007-01-18 Suntory Ltd プロシアニジンの分析方法
JP2012511153A (ja) * 2008-12-04 2012-05-17 シーメンス メディカル ソリューションズ ユーエスエー インコーポレイテッド 自動品質管理装置および自動品質管理方法
US20130209358A1 (en) * 2012-02-13 2013-08-15 Ge Healthcare Limited Radiotracer compositions
JP2013540702A (ja) * 2010-08-18 2013-11-07 ジーイー・ヘルスケア・リミテッド ペプチド放射性トレーサー組成物
JP2014502257A (ja) * 2010-10-22 2014-01-30 ピラマル イメージング ソシエテ アノニム 中枢神経系の疾患を画像化、診断及び／又は治療するために使用する化合物
WO2014135860A1 (en) * 2013-03-04 2014-09-12 The University Court Of The University Of Glasgow Methods, unit and device relating to the manufacture, processing, synthesising or screening of radiopharmaceutical compositions
JP2015531865A (ja) * 2012-08-13 2015-11-05 ザ・ジェネラル・ホスピタル・コーポレイションＴｈｅ Ｇｅｎｅｒａｌｈｏｓｐｉｔａｌ Ｃｏｒｐｏｒａｔｉｏｎ ミトコンドリア複合体ｉの定量マッピング用システムおよび方法
US20170368534A1 (en) * 2014-10-23 2017-12-28 The University Of Hull Monolithic body
WO2019185933A1 (en) * 2018-03-29 2019-10-03 Ge Healthcare Limited Solid phase extraction

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN111333638A (zh) * 2020-03-17 2020-06-26 四川大学华西医院 18f标记的异喹啉并哒嗪酮类化合物及其合成方法和应用

Patent Citations (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH07503960A (ja) * 1992-02-14 1995-04-27 マリンクロッド・インコーポレイテッド 安定化放射性医薬品キット
JP2006514915A (ja) * 2002-03-01 2006-05-18 ダイアックス、コープ Ｋｄｒおよびｖｅｇｆ／ｋｄｒ結合ペプチドならびに診断および治療におけるその使用
JP2007010487A (ja) * 2005-06-30 2007-01-18 Suntory Ltd プロシアニジンの分析方法
JP2012511153A (ja) * 2008-12-04 2012-05-17 シーメンス メディカル ソリューションズ ユーエスエー インコーポレイテッド 自動品質管理装置および自動品質管理方法
JP2013540702A (ja) * 2010-08-18 2013-11-07 ジーイー・ヘルスケア・リミテッド ペプチド放射性トレーサー組成物
JP2014502257A (ja) * 2010-10-22 2014-01-30 ピラマル イメージング ソシエテ アノニム 中枢神経系の疾患を画像化、診断及び／又は治療するために使用する化合物
US20130209358A1 (en) * 2012-02-13 2013-08-15 Ge Healthcare Limited Radiotracer compositions
JP2015531865A (ja) * 2012-08-13 2015-11-05 ザ・ジェネラル・ホスピタル・コーポレイションＴｈｅ Ｇｅｎｅｒａｌｈｏｓｐｉｔａｌ Ｃｏｒｐｏｒａｔｉｏｎ ミトコンドリア複合体ｉの定量マッピング用システムおよび方法
WO2014135860A1 (en) * 2013-03-04 2014-09-12 The University Court Of The University Of Glasgow Methods, unit and device relating to the manufacture, processing, synthesising or screening of radiopharmaceutical compositions
US20170368534A1 (en) * 2014-10-23 2017-12-28 The University Of Hull Monolithic body
WO2019185933A1 (en) * 2018-03-29 2019-10-03 Ge Healthcare Limited Solid phase extraction

Also Published As

Publication number Publication date
KR20240000562A (ko) 2024-01-02
EP4330662A1 (en) 2024-03-06
EP4330662B1 (en) 2025-09-03
PL4330662T3 (pl) 2025-11-12
IL307946A (en) 2023-12-01
ES3050308T3 (en) 2025-12-19
CN117222890A (zh) 2023-12-12
US20240302338A1 (en) 2024-09-12
CA3217818A1 (en) 2022-11-03
WO2022229155A1 (en) 2022-11-03
EP4330662C0 (en) 2025-09-03
AU2022264815A1 (en) 2023-10-26
GB202105950D0 (en) 2021-06-09

Similar Documents

Publication Publication Date Title
JP2024518319A (ja) 分析用ｈｐｌｃ
Gustafsson et al. Combined PET and microdialysis for in vivo estimation of drug blood-brain barrier transport and brain unbound concentrations
Bading et al. Pharmacokinetics of the thymidine analog 2′-fluoro-5-methyl-1-β-D-arabinofuranosyluracil (FMAU) in tumor-bearing rats
Kim et al. Reinvestigation of the synthesis and evaluation of [N-methyl-11C] vorozole, a radiotracer targeting cytochrome P450 aromatase
Gee et al. Synthesis and evaluation of [11C] SB207145 as the first in vivo serotonin 5-HT4 receptor radioligand for PET imaging in man
Velikyan et al. GMP production of [68Ga] Ga-BOT5035 for imaging of liver fibrosis in microdosing phase 0 study
Ismail et al. Evaluation of [11C] methyl-losartan and [11C] methyl-EXP3174 for PET imaging of renal AT1receptor in rats
Wadsak et al. 18F fluoroethylations: different strategies for the rapid translation of 11C-methylated radiotracers
Waterhouse et al. Synthesis of [1–11C] Butanol via a facile solid phase extraction protocol
HK40109526B (en) Analytical hplc
HK40109526A (en) Analytical hplc
EP4442285A1 (en) Stabilized radiopharmaceutical composition
EP3339309B1 (en) Radioactive halogen-labeled pyrido[1,2-a]benzimidazole derivative compound
Pehlivanoglu et al. Development and validation of a UV-Radio-HPLC method to assess chemical and radiochemical purity of [68Ga] Ga-PSMA-11
Almeida et al. Absolute quantitation of iodine-123 epidepride kinetics using single-photon emission tomography: comparison with carbon-11 epidepride and positron emission tomography
Nandy et al. The possibility of a fully automated procedure for radiosynthesis of fluorine-18-labeled fluoromisonidazole using a simplified single, neutral alumina column purification procedure
Wang et al. Development and validation of a HPLC method for the determination of chemical and radiochemical purity of O-(2-[18F] fluoroethyl-L-tyrosine ([18F] FET)), a PET radiotracer for the imaging of brain tumor
US20240005439A1 (en) Imaging methods and radiotracers for use therein
KR101850479B1 (ko) [18F]플루오로-도파의 중성 pH 안정화 방법
US8802053B2 (en) Radio-methyl vorozole and methods for making and using the same
JP6527736B2 (ja) 放射性医薬組成物
JPWO1999008709A1 (ja) 安定な放射性医薬品
Gurin et al. Study of the Purification of 177Lu-DOTAELA Complex
Ishiwata et al. Brain tumor accumulation and plasma pharmacokinetic parameters of 2′-deoxy-5-18F-fluorouridine
Shimizu et al. Automated cassette-based synthesis, metabolism, and dosimetry of [18F] ApaScan, a PET tracer for aldosterone synthase imaging

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20250425

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20250425

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20251226

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20260106

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20260327